Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Biogen : dips as strategy post Alzheimer's setback fails to impress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2019 | 11:31am EDT
A sign marks a Biogen facility in Cambridge

(Reuters) - Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

As the company's lead products Tecfidera and Spinraza face near term challenges, analysts have called for "aggressive" business development measures to fill the void left by the discontinuation of aducanumab.

Biogen, during its post-earnings call, highlighted its pipeline opportunities and signaled that it was in a position to pursue M&A deals and late-stage opportunities.

"The plan A was always to prepare Biogen for growth even without aducanumab," Chief Executive Officer Michel Vounatsos said. "I believe Biogen is set to rebound and I fundamentally believe we will be back."

However, analysts remained unconvinced and said that the company did not provide specific plans for growth.

"I don't think they've given investors a concrete path here that they're moving the company forward," Mizuho Securities analyst Salim Syed told Reuters.

The company's growth driver Spinraza, used for treating spinal muscular atrophy, brought in $518 million in the quarter, beating Refinitiv IBES estimates of $486.4 million.

Spinraza is currently the only U.S.-approved treatment for the rare disease that can lead to paralysis, breathing difficulty and death.

However, looming competition from treatments such as Novartis AG's Zolgensma and Roche's risdiplam is expected to weigh on the long-term prospects for Spinraza.

Sales of Biogen's top-selling multiple sclerosis drug Tecfidera came in at $999 million in the quarter, but narrowly missed consensus estimates.

The drug is facing patent challenges and losing market share to newer treatments like Roche's Ocrevus, which is expected to outpace Tecfidera sales by 2021, according to Refinitiv.

Biogen said it expects a nearly $125 million reduction in operating expenses during the year related to the discontinuation of aducanumab, with net savings of about $80 million.

"Biogen's management appears mostly inclined to deploy these savings and the rest of their excess capital for share repurchases rather than for transformative acquisitions," SVB Leerink analyst Geoffrey Porges said.

Net income attributable to the company rose 20 percent to $1.41 billion, in the quarter ended March 31. (https://bit.ly/2L1UlKL)

On an adjusted basis, the company earned $6.98 per share on revenue of $3.49 billion. Analysts had expected $6.87 per share on revenue of $3.39 billion.

Shares of the company fell 2 percent to $225.77 in morning trading.

(Reporting by Manojna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber)

By Saumya Joseph and Manojna Maddipatla

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC.
07:31aBiogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Inde..
GL
09/16BIOGEN : Eisai and biogen to discontinue phase iii clinical studies of bace inhi..
AQ
09/13BIOGEN : New Research Demonstrate Biogen's Continued Commitment to Improve Care ..
AQ
09/13BIOGEN : Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhi..
PR
09/12BIOGEN : to Report Secondary Quarter 2019 Financials October 22,2019
AQ
09/12BIOGEN INC. : - New Data Presented at ECTRIMS Reinforce Long-term Benefits of TE..
AQ
09/12New Research Demonstrate Biogen's Continued Commitment to Improve Care of Pat..
GL
09/11BIOGEN : New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA..
AQ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/28BIOGEN : to Present at the Morgan Stanley 17th Annual Global Healthcare Conferen..
AQ
More news
Financials (USD)
Sales 2019 14 128 M
EBIT 2019 7 418 M
Net income 2019 5 724 M
Finance 2019 482 M
Yield 2019 -
P/E ratio 2019 7,87x
P/E ratio 2020 7,90x
EV / Sales2019 3,08x
EV / Sales2020 2,84x
Capitalization 44 028 M
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 260,20  $
Last Close Price 238,70  $
Spread / Highest target 47,9%
Spread / Average Target 9,01%
Spread / Lowest Target -15,0%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-20.68%43 552
CSL LIMITED24.59%71 654
ALEXION PHARMACEUTICALS10.31%24 338
GRIFOLS16.64%17 681
SAMSUNG BIOLOGICS CO LTD--.--%16 399
BIOMARIN PHARMACEUTICAL INC.-12.85%13 318